Analyzing the influence of expanding multispecialty adoption of robotic surgery on robotic urologic care: A decade-long assessment of two Canadian academic hospitals

Ahmed Ibrahim1, Imad Matta1, Ahmed S. Zakaria2, Abdulghani Khogeer1, Nick Lee1, Tawfik Elseherbini1, David Dan Nguyen3, Nicholas J. Corsi4, David Bouhadana5, Adel Arezki5, Anindyo Chakraborty6, Malek Meskawi1, Assaad Elhakim1, Kevin C. Zorn1

1Division of Urology, University of Montreal Hospital Center, Montreal, Canada; 2Division of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada; 3Division of Urology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 4University of Texas Southwestern Medical Center Dallas, TX, United States; 5Division of Urology, McGill University, Montreal, QC, Canada; 6Faculty of Medicine, McGill University, Montreal, QC, Canada


Published online February 15, 2024

Corresponding Author: Dr. Kevin Zorn, Division of Urology, University of Montreal Hospital Center, Montreal, QC, Canada; zorn.chumurology@gmail.com

***

ABSTRACT

Introduction: Most robot-assisted surgery (RAS) systems in Canada are donor-funded, with constraints on implementation and access due to significant costs, among other factors. Herein, we evaluated the impact of the growing multispecialty use of RAS on urologic RAS access and outcomes in the past decade.

Methods: We conducted a retrospective review of all RAS performed by different surgical specialties in two high-volume academic hospitals between 2010 and 2019 (prior to the COVID pandemic). The assessed outcomes included the effect of increased robot access over the years on annual robotic-assisted radical prostatectomy (RARP) volumes, surgical waiting times (SWT), and pathologically positive surgical margins (PSM). Data were collected and analyzed from the robotic system and hospital databases.

Results: In total, six specialties (urology, gynecology, general, cardiac, thoracic, and otorhinolaryngologic surgery) were included over the study period. RAS access by specialty doubled since 2010 (from three to six). The number of active robotic surgeons tripled from 7 surgeons in 2010 to 20 surgeons in 2019. Moreover, there was a significant drop in average case volume, from a peak of 40 cases in 2014 to 25 cases in 2019 (p=0.02). RARP annual case volume followed a similar pattern, reaching a maximum of 166 cases in 2014, then declining to 137 cases in 2019. The mean SWT was substantially increased from 52 days in
INTRODUCTION
Surgery has become substantially technology-driven, with robot-assisted surgery (RAS) being a notable innovation in several surgical fields [1]. RAS overcomes the ergonomic limitations of conventional laparoscopy and offers various advantages [1, 2]. With the emergence of new technologies, the global market for surgical robots was valued at USD 4.4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 18.0% from 2023 to 2030 [3]. According to Intuitive Surgical 2010 Annual Report, the da Vinci® surgical (DVS) system was predominantly used for prostatectomies and hysterectomies, accounting for over 70% of procedures. Robotic-assisted radical prostatectomy (RARP). Several studies have demonstrated the safety and effectiveness of RARP, highlighting its benefits compared to open radical prostatectomy (ORP) and conventional laparoscopy, such as reduced blood loss, transfusion rate, complications, and hospital stay [1-3]. Furthermore, compared to conventional laparoscopy, RARP enables larger degrees of wrist movement, increased work efficiency and precision with 3-dimensional visualization of the operative field [1,3].

While urology has achieved significant growth in RAS utilization, other specialties such as general surgery, gastrointestinal, cardiothoracic, gynecologic, and otolaryngologic have also witnessed increasing adoption of robotic surgery in recent years [2]. In Canada, the majority of RAS systems (30 DaVinci robots) have been funded by hospital foundations through philanthropy donations, thereby limiting their availability and utilization. This expanded use of RAS across specialties, especially in urology, poses significant challenges given the limited resources in the Canadian socialized, single-payer, health care system. However, the impact of the increased utilization of RAS on urological access, surgical volumes, and outcomes remains unknown. Therefore, our study aimed to assess the effects of the growing multi-specialty use of RAS coupled with a limited number of robotic systems, specifically on urological access and oncological outcomes over the past decade.

METHODS
Study design and data collection
After obtaining the ethics approval for this retrospective, multi-institutional study, a review with patients involved in all RAS procedures performed in different surgical specialties (urology, gynecology, general, cardiac, thoracic, and otolaryngologic surgery) between 2010 and 2014 to 73 days in 2019; however, PSM rates were not affected by the reduction in surgical volumes (p<0.05).

Conclusions: Over the last decade, RAS access by specialty has increased at two Canadian academic centers due to growing multispecialty use. As there was a fixed, single-robotic system at each of the hospital centers, there was a substantial reduction in the number of RAS performed per surgeon over time, as well as a gradual increase in the SWT. The current low number of available robots and unsustainable funding resources may hinder universal patient access to RAS.
2019 at the Centre Hospitalier de l'Université de Montréal (CHUM) and the Hôpital du Sacré-Cœur-de-Montréal (HSCM) was conducted. Both academic centers are both located in the large metropolitan city, namely Montréal, Québec, Canada. The decision for these years included the initiation of RAS in 2010 and 2019 year to avoid clinical impact from the COVID pandemic. Over the same period, another retrospective review of a prospectively maintained RARP institutional review board-approved database in the same academic centers. The data was collected from the institutions’ electronic medical records (EMR) platform OACIS. The platform allowed access to the electronic surgical scheduling system (OPERA) and the resource management systems. Procedural data was also collected from each of the DVS robotic systems. The assessed outcomes included the effect of increased robot access over the years on annual RARP volumes, SWT, and pathological positive surgical margins (PSM). The measured variables included the total number of RAS procedures, active RAS surgeons, and average number of cases per active surgeon across different surgical specialties, total RARP volume, SWT in days, and PSM (including the total percentage of positive margins, percentage of positive pT2 margins, and percentage of positive pT3 margins).

**Statistical analysis**
Data were collected and analysed from the robotic system and hospital databases. All analyses were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Descriptive statistics, such as means and standard deviations, were calculated to summarize the baseline characteristics. The statistical significance level was set at p < 0.05.

**RESULTS**
In total, six specialties (urology, gynecology, general, cardiac, thoracic, and otorhinolaryngologic surgery) developed RAS programs over the studied period, and RAS access by specialty doubled from 3 (2010) to 6 (2019) (Figure 1). In terms of procedural volume, urology remained at the top among surgical specialties with more than 42% of the total procedure volume (Figure 1). The number of active robotic surgeons tripled from 7 surgeons in 2010 to 20 surgeons in 2019. Urologic and gynecologic surgeons together represented half of the total number of active surgeons. There was a gradual decrease in the number of RAS procedures performed per surgeon over time. Over the years, there was a significant decrease in the average RAS volume per active robotic surgeon (all surgical specialties included), from a high of 40 cases in 2014 to 25 cases in 2019 (Figure 2).

The total RARP surgical volume between 2010 and 2019 was 1339 procedures across the two centers, ranging from a low of 94 procedures in 2010 to a high of 166 procedures in 2014. There were 802 procedures performed at the HSCM, while the CHUM performed 537 procedures throughout the same period.

With regards to urological RAS, there was a general decreasing trend in RARP surgical volume over time. There were two active RARP surgeons performing these procedures. Surgeon 1 performed 925 procedures between 2010 and 2019 with a low of 35 procedures in 2010 and a high of 127 procedures in 2014. Surgeon 2 performed 414 procedures in total, with a low of 25 procedures in 2017 and a high of 59 procedures in 2010. The mean SWT for RARP procedures ranged from a low of 52 days in 2014 to a high of 118 days in 2011. Throughout the study
period, there was a gradual increase in the mean SWT. The total percentage of positive margins on pathology ranged between 13.1% in 2018 and 29.4% in 2011. The percentage of positive pT2 margins ranged between 5.1% in 2019 and 21.2% in 2010. The percentage of positive pT3 margins ranged between 7.4% in 2010 and 16.2% in 2014. A decreasing trend was observed in PSM between 2010 and 2019, and PSM rates were not affected by the increase in mean SWT or the decrease in surgical volumes (Figure 3).

DISCUSSION
Minimally invasive robotic surgery offers numerous benefits across various surgical fields, including urology. The confined and intricate nature of urological pelvic procedures makes it challenging to perform using conventional laparoscopic or open surgery. Robotic assistance however addresses these challenges by providing improved access, maneuverability, and visualization. The introduction of robot-assisted radical prostatectomy (RARP) in 2000 by Binder et al. revolutionized the field of urology [4]. RARP has demonstrated superior outcomes compared to open radical prostatectomy (ORP), including reduced blood loss, shorter hospital stays, and reduced postoperative complications [5-8]. Additionally, the adoption of robotic surgical systems has expanded beyond urology to include procedures such as nephrectomy (partial and radical), cystectomy and adrenalectomy.

In Canada, the publicly funded healthcare system and limited market size pose inherent challenges for implementing robotic surgery. Access to medical devices is often delayed, resulting in longer surgical wait times and limited availability of robotic technology. Unlike in the United States, where hospitals purchase robots, all Da Vinci Surgical (DVS) systems in Canada have been acquired through donor-funded initiatives, restricting their widespread implementation. Consequently, Canadian patients may face longer travel distances for surgery and extended surgical wait times. The use of robotic surgery has experienced exponential growth worldwide, particularly in urology, but its expansion into other specialties has led to a plateau in the growth of robotic prostatectomies [9, 10]. Therefore, our study aimed to assess the effects of the growing multi-specialty use of RAS on urological access and outcomes over the past decade.

In the present study, we observed that RAS access by specialty has increased in the past decade (2010-2019) due to growing multi-specialty use. Additionally, there was a significant reduction in number of RAS performed per surgeon over time, with a corresponding increase surgical wait time. Fortunately, however, the drop in annual urology surgical volumes was not associated with worse oncological outcomes. This is likely related to the fact that all urological RAS surgeons had extensive experience, fellowship training and had overcome their learning curves.

Moreover, our findings indicate a notable increase in specialty-specific access to robotic-assisted surgery (RAS), with the number of specialties offering RAS doubling from 3 in 2010 to 6 in 2019. Additionally, we observed a consistent decrease in the number of RAS procedures performed by individual surgeons over time. The average case volume per active robotic surgeon, encompassing all specialties, showed a significant decline from a peak of 40 cases in 2014 to 25 cases in 2019. With regards to a minimum number of cases per year per
surgeon to maintain proficiency, this may be of concern with the addition of other surgeons in upcoming years with a fixed number of robotic systems.

In line with this trend, the annual case volume for robot-assisted radical prostatectomy (RARP) exhibited a similar pattern. It reached its highest point of 166 cases in 2014, but subsequently decreased to 113 cases in 2017 and 137 cases in 2019. Furthermore, our analysis revealed a significant increase in SWT throughout the study period. The average SWT rose from 52 days in 2014 to 73 days in 2019. While the precise impact of prolonged waiting on disease recurrence remains uncertain, there is a growing concern about the potential negative influence of extended waiting periods on patient outcomes, particularly in terms of psychological well-being and oncological progression as well as secondary treatment for disease recurrence. Despite the surgical delays and reduction in surgical volumes, overall positive surgical margins (PSM) from RARP remained relatively unaffected in the present study, decreasing from 29.6% in 2010 to 17.5% in 2019.

It is important to note that the cost-effectiveness of robotic-assisted radical prostatectomy (RARP) in Canada's healthcare system continues to remain a topic of debate. While RARP offers several benefits, including improved surgical outcomes, its higher equipment costs (2000-3000$ CAD more per case in disposables) compared to laparoscopic or open surgeries need to be considered. Previous economic assessments have shown favorable cost-effectiveness for RARP when the annual case volume per system exceeds 150 cases. However, more research is needed to provide conclusive evidence on the cost-effectiveness of RARP [11-15].

It is crucial to acknowledge the limitations of our study. Firstly, our research was conducted in only two academic hospitals within Canada and in a single province, limiting the generalizability of the findings. National multispecialty studies are needed to validate these results and inform future policies on the coverage and accessibility of robotic-assisted surgery (RAS). Additionally, such studies can contribute to the development of sustainable strategies that enhance efficiency and accessibility of RAS. Perhaps also to consider a maximum number of surgeons or specialties per robotic platform to protect against significant dilutional effects and access limitations we have observed. Furthermore, our study was conducted by a limited number of highly trained robotic surgeons. Additionally, the retrospective design of our study restricts the analysis of other variables, such as the complexity of specific procedures in non-RARP cases. Therefore, ongoing studies with regression analyses to examine trends over time are still required.

CONCLUSIONS
Over the last decade, RAS access by specialty has significantly increased in Canada. However, our study demonstrates a gradual decline in the number of RAS performed per surgeon over time as well as a gradual increase in the mean SWT with a fixed and limited number of robotic platforms this past decade. While significant or comprehensive conclusions regarding robotic surgery programs cannot be drawn from this two-institution retrospective study alone, the lack of growth and acquisition of additional surgical robots, the significant costs related to the use of surgical robots, the constant increase in RAS demand
and the increase in RAS application across different surgical specialties in Canada will eventually affect patient access to RAS.
REFERENCES


FIGURES AND TABLES

Figure 1. Total procedure volume accessed by speciality over time.

Figure 2. Total procedures vs. number of active surgeons vs. average cases per active surgeon.
**Figure 3.** Total surgical volume and positive surgical margins over time